

Meditation makes me sick: Meditation and sensitivity to parasympathetic nervous system stimulation

Silvie Kotherová¹, Jakub Cigán¹, Milan Sepši², Lenka Krajčíková³, Mária Holická², Jiří Jarkovský⁴

Laboratory for Experimental Research of Religion (LEVYNA), Masaryk University
 Department of Internal Cardiology Medicine, Masaryk University
 Department of Psychology, Faculty of Arts, Masaryk University
 Institute of Biostatistics and Analyses, Masaryk University



- □ Meditations are in medical research literature approached as relaxation techniques with beneficial health effects (stress reduction, improvement of cardiovascular system) [1]. However, meditation and health research suffers from many theoretical and methodological shortcomings [2, 3] supporting only positive effects of meditations. Negative effects thus have been fairly omitted in a scientific literature.
- Meditation, in general, stimulates parasympathetic nervous system and should lead to relaxed states. Yet in our previous study aimed every 6th participant reported during meditation head spinning, nausea, extreme sweating, over warming and faintness. In this project we focused on these effects of meditation practice.

STATISTICAL ANALYSES

□For comparison of dependent within-subject data was used Wilcoxon paired test.

□For comparison of independent between-subjects data was used Kruskal-Wallis test.

RESULTS

□ DC significantly increased (p < .001) in both males (p = .013) and females (p = .001) during meditation (Phase 2). Normalized HF significantly increased and normalized LF significantly decreased during meditation (Phase 2) in all participants (p = .008) (see Tab. 1).

HYPOTHESES

- □ H1: There will be a significant increase in parasympathetic autonomous nervous activity and decrease or no change in sympathetic autonomous nervous activity during meditation (Phase 2) compared to the time before meditation (Phase 1).
 - □ Activity of parasympathetic nervous system is detectable in increase of normalized power in the high frequency range (HF normalized) and decrease or no change of normalized power in low frequency range (LF normalized) of a heart rate [4, 5].
- H2: Parasympathetic activity (HF normalized) during meditation (Phase 2) will be significantly increased in participants scoring high on the Nausea Profile compared to other participants.

PARTICIPANTS & METHODS


 \Box Participants: 57 university students (42 females and 15 males, mean age = 23). Participants were divided according to their Nausea Profile score into the three groups (19 in each).

Within-subject experimental design consisted of three phases: rest phase before meditation (Phase 1), meditation (Phase 2) and after meditation (Phase 3).
Treatment: Meditation practice called Anápána sati aimed at breath was operationalized as counting breaths while having eyes closed.
Questionnaire: The Nausea Profile [7].

PROCEDURE

- Participant received three-lead Holter EKG (MARS GE Medical) and noninvasive hemodynamic continual monitoring of blood pressure CNAP 500 HD and went through three phases. In post-meditation phase participant filled in the Nausea Profile and an open questionnaire for subjective report.
- □ Deceleration capacity (DC) [6] of heart rate (HR) was determined as the indicator of a parasympathetic nervous activity. For comparison of parasympathetic and sympathetic nervous activity were stated following parameters [5]: heart rate variability (HRV), normalized power in the low

- □ HF normalized significantly increased in Phase 2 in comparison to the Phase 1, but only in participants who scored medium (15–26) (from mdn = 34.6 (15.3; 79.7) to mdn = 55 (13; 78), difference mdn = -12.1 (-44.3; 26.8), p = .031)and high (≥ 27) (from mdn = 25.2 (11.5; 52.1) to mdn = 35.6 (11.8; 74.2), difference mdn = -5.41 (-52.58; 23.21), p = .033) in the Nausea Profile (see Fig. 1).
- Meditation increased parasympathetic nervous activity in all participants. In some individuals rapid activation of a parasympathetic nervous system during meditation led to nauseous feelings.



DISCUSSION

Both hypotheses were tentatively supported in analyses. Remaining issues:

Unexpectedly some measured heart activity parameters didn't correspond with each other appropriately.

frequency range (LF normalized), normalized power in the high frequency range (HF normalized) with efferent vagal activity as a major contribution and LF/HF ratio as a marker of sympathetic vagal balance.

0	All participants	Sex		p1
	N = 57 Median (5 th ; 95 th percentile)	Females N = 42 Median (5 th ; 95 th percentile)	Males N = 15 Median (S th ; 95 th percentile)	
DC		x 50 65 *		
Phase 1	10.3(6.7;18.2)	9.90(6.69;18.15)	11.1(7.5;17.7)	0,578
Phase 2	12.3(7.3;30.1)	12.0(7.7;28.7)	15.7(-10.0;34.9)	0,365
Phase 3	9.58(5.91;15.03)	9.08(5.91;13.65)	11.5(6.8;17.8)	0,013
Phase 1 - Phase 2 diff.	-1.48(-17.19;2.03)	-1.38(-16.54;1.92)	-4.20(-17.19;5.15)	0,056
Phase 2 - Phase 3 diff.	3.15(-3.42;21.02)	3.15(-1.52;18.60)	4.08(-6.32;26.60)	0,835
p2	<0.001	0,001	0,013	
p3	<0.001	<0.001	0,035	
LF normalized				
Phase 1	69(32;89)	69(34;89)	71(20;80)	0,905
Phase 2	61(25;90)	63(27;89)	59(22;90)	0,587
Phase 3	74(38;89)	72(38;88)	78(56;91)	0,354
Phase 1 - Phase 2 diff.	4.94(-23.21;43.26)	4.32(-23.21;37.40)	12.0(-18.6;52.6)	0,566
Phase 2 - Phase 3 diff.	-8.82(-44.97;20.07)	-6.37(-39.03;20.07)	-23.8(-65.4;15.3)	0,130
p2	0,008	0,024	0,116	
р3	<0.001	0,007	0,011	
HF normalized				
Phase 1	30.6(11.5;67.5)	30.9(11.5;65.5)	28.6(19.6;79.7)	0,905
Phase 2	39.0(10.4;74.9)	37.3(11.0;72.7)	41.2(10.4;78.4)	0,587
Phase 3	26.2(11.2;62.0)	27.5(12.2;62.0)	22.3(8.8;43.9)	0,354
Phase 1 - Phase 2 diff.	-4.94(-43.26;23.21)	-4.32(-37.40;23.21)	-12.0(-52.6;18.6)	0,566
Phase 2 - Phase 3 diff.	8.82(-20.07;44.97)	6.37(-20.07;39.03)	23.8(-15.3;65.4)	0,130
p2	0,008	0,024	0,116	
p3	<0.001	0,007	0,011	

Tab.1

p1 is statistical significance of difference between groups evaluated by the Kruskal–Wallis test.

p2 is statistical significance of difference within the same individuals in Phase 1 and Phase 2 evaluated by Wilcoxon paired test.

p3 is statistical significance of difference within the same individuals in Phase 2 and Phase 3 evaluated by Wilcoxon paired test.

Continuous blood pressure change measures are expected to reveal more and are being analyzed in these days.

RESFERENCES

1 Olex, S., Newberg, A., & Figueredo, V. M. (2013). Meditation: Should a cardiologist care? *International Journal of Cardiology*, *168*(3), 1805-1810.

2 Brook, R. D., Appel, L. J., Rubenfire, M., Ogedegbe, G., Bisognano, J. D., Elliott, W. J., … Rajagopalan, S. (2013). Beyond Medications and Diet: Alternative Approaches to Lowering Blood Pressure: A Scientific Statement From the American Heart Association. *Hypertension*, 61(6), 1360-1383.

3 Ospina, M. B., Bond, T. K., Karkhaneh, M., Tjosvold, L., Vandermeer, B., Liang, Y., … Klassen, T. P. (2009). *Meditation Practices for Health: State of the Research. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-02-0023.)* (1–AHRQ Publication, 07-E010). Rockville: Agency for Healthcare Research and Quality.

4 Murata, T., Takahashi, T., Hamada, T., Omori, M., Kosaka, H., Yoshida, H., & Wada, Y. (2004). Individual Trait Anxiety Levels Characterizing the Properties of Zen Meditation. *Neuropsychobiology*, *50*(2), 189-94.

5 Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. (1996). Heart rate variability standards of measurement, physiological interpretation, and clinical use. *Circulation*, 93(5), 1043-1065.
6 Bauer, A., Kantelhardt, J. W., Barthel, P., Schneider, R., Mäkikallio, T., Ulm, K., … Schmidt, G. (2006). Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. *The Lancet*, 367(9523), 1674-1681.

7 Muth, E. R., Stern, R. M., Thayer, J. F., & Koch, K. L. (1996). Assessment of the multiple dimensions of nausea: The Nausea Profile (NP). *Journal of Psychosomatic Research*, 40(5), 511-520.









LABORATORY FOR EXPERIMENTAL RESEARCH OF RELIGION